Andrew K. Silvernail
Andrew K. Silvernail's purchase track record
Andrew K. Silvernail has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/30/2026 | IP | $2.00M | -20.4% | +3.8% | +7.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
International Paper (IP) faces valuation dip and EMEA business review. The stock has fallen about 23% and is now considered below fair value by analysts. Management is reviewing options for its EMEA packaging business, including possible offers. Recent trading saw the shares move higher, reflecting the ongoing discussion of the strategic review. The situation adds focus on valuation and the outcome of the EMEA decision.
Transaction History
| SYK | ▲ Buy | Grant | 762 | $0 | 5/6/2026 | View on chart |
| IP | ▲ Buy | Open Market | 50,000 | $2.0M | 1/30/2026 | View on chart |
| SYK | ▲ Buy | Option Exercise | 4,570 | $442K | 1/15/2026 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 1,229 | $442K | 1/15/2026 | View on chart |
| SYK | ▲ Buy | Grant | 560 | $0 | 5/8/2025 | View on chart |
| SYK | ▲ Buy | Option Exercise | 3,795 | $353K | 2/3/2025 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 903 | $353K | 2/3/2025 | View on chart |
| SYK | ▲ Buy | Grant | 653 | $0 | 5/9/2024 | View on chart |
| SYK | ▲ Buy | Option Exercise | 4,355 | $353K | 12/5/2023 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 1,215 | $354K | 12/5/2023 | View on chart |
| SYK | ▲ Buy | Grant | 705 | $0 | 5/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.